MIST News and Press, Milestone Pharmaceuticals Inc. From 08/10/23

Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update Canada NewsWire NDA submission for etripamil in patients with PSVT expected in October 2023 Data featured during oral session at Heart Rhythm 2023 A...

2023-06-20 18:18:55 ET More on Milestone: Milestone Pharmaceuticals GAAP EPS of -$0.35 beats by $0.05, revenue of $1M Milestone Pharma receives $125M financing to support etripamil development For further details see: Jefferies downgrades Milestone to hold, cites...

Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet Canada NewsWire - Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventric...

2023-05-22 14:37:35 ET Summary Today, we take a deeper look at Milestone Pharmaceuticals Inc. for the first time on Seeking Alpha. The company's primary drug candidate has a novel delivery system and should have an NDA submitted around it next quarter. Where does Milestone Pha...

Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate Canada NewsWire -  Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted...

2023-05-11 09:05:07 ET Milestone Pharmaceuticals press release ( NASDAQ: MIST ): Q1 GAAP EPS of -$0.35 beats by $0.05 . Revenue of $1M. As of March 31, 2023, Milestone had cash, cash equivalents, and short-term investments of $101.0 million and 33.4 million common ...

Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update Canada NewsWire - NDA submission for etripamil in patients with PSVT currently on track for 3Q23 - Company to host virtual KOL event focused on etripamil f...

Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate Canada NewsWire - Cardiac Electrophysiology Key Opinions Leaders to include Paul Dorian , MD, and Jonathan Piccini , MD ...

Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference Canada NewsWire MONTREAL and CHARLOTTE, N.C. , April 12, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the de...

2023-03-29 16:59:22 ET Milestone Pharmaceuticals press release ( NASDAQ: MIST ): Q4 GAAP EPS of -$0.31. Revenue of $3.5M. As of December 31, 2022, Milestone had cash, cash equivalents, and short-term investments of $64.6 million, compared to $114.1 million as of Decemb...